Innogenetics and Bio-Rad enter into a non-exclusive licensing agreement for HIV-2 patents
Under the agreement, Innogenetics will be granted a non-exclusive license to Bio-Rad's intellectual property in the field of HIV-2 immunoassays and, consequently, all legal proceedings between Innogenetics, Institut Pasteur, Bio-Rad Pasteur, and Bio-Rad Laboratories b.v. will be terminated. The HIV-2 license granted to Innogenetics covers all territories (except the USA and Canada) and runs until the expiration of the last to expire of the licensed patents.
The proceedings were initiated by the aforementioned parties in 1998 and were related to the Institute Pasteur's European patents EP 239 425 and EP 283 327. Based on these patents, claims were pending against Innogenetics at the Courts of Antwerp and Gent, respectively.
In addition, Bio-Rad will be granted an option to Innogenetics HCV genotyping patents. This option is non-exclusive and covers all territories.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.